There is a connection between obesity, diabetes and cancer that is well-accepted by the medical and scientific communities. Epidemiological evidence suggests that people with diabetes are at significantly higher risk for many forms of cancer. Type 2 diabetes and cancer share many risk factors, but detailed molecular/ mechanistic links between the two diseases are incompletely understood.
Moreover, some medications used to treat cancer are associated with hyperglycemia and diabetes, and a reverse pattern is also noted - that some medications used to ameliorate hyperglycemia and diabetes are associated with increased risk of cancer.
The scope of this Research Topic targets new mechanisms linking dysregulated metabolism in these two disease areas. Topics of interest include, but are not limited to:
From the cancer perspective, what metabolic changes underpin cancer development (e.g., oncometabolites), loss of metabolic tumor suppressors, high-jacking micro-nutrients?
Are cancer-causing metabolic changes precipitated by current/ planned diabetes interventions (e.g., insulin, or beta cell proliferation agents)?
New ways to temper cancer cell proliferation while coordinately tempering obesity/ diabetes (e.g., lipids, fatty acids).
Is the metabolic regulation of epigenetics in cancer and in diabetes aligned, or opposing?
Diabetes and cancer are considered to be on opposite sides of the same coin - the aim of this Research Topic is to highlight new mechanistic insights that may collectively unveil new ways of approaching treatment of one disease, without risking the occurrence of the other.
There is a connection between obesity, diabetes and cancer that is well-accepted by the medical and scientific communities. Epidemiological evidence suggests that people with diabetes are at significantly higher risk for many forms of cancer. Type 2 diabetes and cancer share many risk factors, but detailed molecular/ mechanistic links between the two diseases are incompletely understood.
Moreover, some medications used to treat cancer are associated with hyperglycemia and diabetes, and a reverse pattern is also noted - that some medications used to ameliorate hyperglycemia and diabetes are associated with increased risk of cancer.
The scope of this Research Topic targets new mechanisms linking dysregulated metabolism in these two disease areas. Topics of interest include, but are not limited to:
From the cancer perspective, what metabolic changes underpin cancer development (e.g., oncometabolites), loss of metabolic tumor suppressors, high-jacking micro-nutrients?
Are cancer-causing metabolic changes precipitated by current/ planned diabetes interventions (e.g., insulin, or beta cell proliferation agents)?
New ways to temper cancer cell proliferation while coordinately tempering obesity/ diabetes (e.g., lipids, fatty acids).
Is the metabolic regulation of epigenetics in cancer and in diabetes aligned, or opposing?
Diabetes and cancer are considered to be on opposite sides of the same coin - the aim of this Research Topic is to highlight new mechanistic insights that may collectively unveil new ways of approaching treatment of one disease, without risking the occurrence of the other.
